MCRB

Seres Therapeutics Inc

2.09

Nov 04 • 3:59 PM ET +0.13 (6.63%)

2.09

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Today, 9:46 AMSeres Therapeutics Inc reports fiscal Q3 2026 results with non-GAAP EPS $-1.63 (-273% YoY) and revenue $593,000 (+69% YoY), misses EPS and revenue estimates

Peers: ACXP CRMD JSPR MESO SPRO INCY ASMB INVA ATRA SCYX

| Held by: VTI VXF IWC PRFZ EES BTEC BUSM AVSC

Scroll to Statements

Index	-
Market Cap	20.77M
Enterprise Value	61.82M
Income	-22.46M
Sales	1.88M
Book/sh	3.51
Cash/sh	1.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	66
IPO	Jun 26, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	11.05
P/B	0.59
P/C	1.33
P/FCF	-
EV/EBITDA	-
EV/Sales	32.88
Quick Ratio	2.11
Current Ratio	2.11
Debt/Eq	1.64
LT Debt/Eq	1.30
Option/Short	Yes / Yes

EPS (ttm)	-2.28
EPS next Y	-2.50
EPS next Q	-1.11
EPS this Y	-699.79%
EPS next Y	34.99%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	-51.99% -52.67%
EPS Y/Y TTM	71.26%
Sales Y/Y TTM	448.44%
EPS Q/Q	120.70%
Sales Q/Q	-
Earnings	Nov 04 BMO
EPS/Sales Surpr.	-62.19% -90.66%

Insider Own	23.57%
Insider Trans	-0.04%
Inst Own	11.40%
Inst Trans	-0.70%
ROA	-18.31%
ROE	-66.57%
ROIC	-28.31%
Gross Margin	-83.17%
Oper. Margin	-4095.43%
Profit Margin	-1192.94%
SMA20	-5.81%
SMA50	-39.42%
SMA200	-69.73%
Trades

Shs Outstand	9.83M
Shs Float	7.60M
Short Float	4.11%
Short Ratio	4.51
Short Interest	0.31M
52W High	29.98 -93.03%
52W Low	1.67 24.78%
Volatility	12.19% 10.32%
ATR (14)	0.25
RSI (14)	35.88
Beta	0.55
Rel Volume	1.37
Avg Volume	69.27K
Volume	95,000

Perf Week	16.76%
Perf Month	-27.93%
Perf Quarter	-56.64%
Perf Half Y	-73.88%
Perf YTD	-85.95%
Perf Year	-84.80%
Perf 3Y	-91.96%
Perf 5Y	-98.51%
Perf 10Y	-99.00%
Recom	1.00
Target Price	17.00
Prev Close	1.96
Price	2.09
Change %	6.63%

Consensus

Strong Buy

Avg. Price Target

$17.00

Implied Upside

+713.4%

Analysts10incl. previous ratings

Rating Distribution6 Buy · 2 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 23, 2026	Initiated	HH.C. Wainwright	Buy	$12	+474.2%
May 08, 2025	Downgrade	CChardan Capital Markets	Buy → Neutral	$6	+187.1%
Oct 24, 2024	Downgrade	JJP Morgan	Neutral → Underweight
Jun 26, 2023	Resumed	OOppenheimer	Outperform	$12	+474.2%
Apr 21, 2023	Initiated	JJP Morgan	Neutral	$7	+234.9%
Jul 23, 2021	Downgrade	GGoldman	Neutral → Sell	$24 → $7	+234.9%
May 18, 2021	Resumed	GGoldman	Neutral	$24	+1,048.3%
Mar 05, 2021	Upgrade	CChardan Capital Markets	Neutral → Buy	$30	+1,335.4%
Sep 18, 2020	Downgrade	CChardan Capital Markets	Buy → Neutral	$32.50 → $27.50	+1,215.8%
Aug 18, 2020	Initiated	PPiper Sandler	Overweight	$40	+1,813.9%
Aug 11, 2020	Upgrade	JJefferies	Hold → Buy	$4 → $29	+1,287.6%
Aug 11, 2020	Reiterated	HH.C. Wainwright	Buy	$8 → $41	+1,861.7%
Apr 30, 2019	Initiated	JJefferies	Hold	$7	+234.9%
Oct 22, 2018	Initiated	CChardan Capital Markets	Buy	$15	+617.7%
Oct 13, 2017	Initiated	OOppenheimer	Outperform	$19	+809.1%
Aug 04, 2017	Reiterated	HH.C. Wainwright	Buy	$15 → $19	+809.1%
Feb 01, 2017	Reiterated	FFBR & Co.	Outperform	$23 → $18	+761.2%
Aug 12, 2016	Reiterated	FFBR Capital	Outperform	$43 → $23	+1,000.5%
Aug 01, 2016	Reiterated	HH.C. Wainwright	Buy	$50 → $15	+617.7%
Aug 01, 2016	Downgrade	BBofA/Merrill	Buy → Neutral

Today 07:12AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press) +6.63%
07:00AM	Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) (GlobeNewswire)
Nov-03-26 07:00AM	Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients (GlobeNewswire) +7.10%
Oct-15-26 07:00AM	Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 (GlobeNewswire)
Sep-08-26 06:00PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.04%
07:00AM	Loading…
Sep-01-26 07:00AM	Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) +5.50%
Aug-05-26 07:12AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press)
07:00AM	Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs (GlobeNewswire)
Jul-08-26 07:00AM	Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment (GlobeNewswire) -12.29%
Jun-25-26 07:00AM	Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (GlobeNewswire)
Jun-05-26 07:00AM	Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 (GlobeNewswire)
May-12-26 07:00AM	Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire)
May-05-26 07:14AM	Seres Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:00AM	Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-04-26 07:00AM	Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease (GlobeNewswire)
07:00AM	Loading…
Apr-20-26 07:00AM	Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 (GlobeNewswire)
Apr-09-26 07:00AM	Seres Therapeutics to Present at CARB-X Investor Day (GlobeNewswire)
Mar-12-26 07:23AM	Seres Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-02-26 04:05PM	Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates (GlobeNewswire)
Feb-12-26 08:29AM	Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash (Benzinga) -41.66%
07:00AM	Seres to lay off staff, pause top program in latest reboot (BioPharma Dive)
07:00AM	Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases (GlobeNewswire)
Jan-06-26 07:00AM	Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy (GlobeNewswire)
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
Nov-24-25 07:00AM	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-05-25 07:00AM	Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.64%
Oct-30-25 07:00AM	Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 (GlobeNewswire) -6.57%
Oct-29-25 07:00AM	Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 (GlobeNewswire)
Oct-14-25 07:00AM	Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (GlobeNewswire)
07:00AM	Loading…
Sep-23-25 07:00AM	Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway (GlobeNewswire) +6.30%
Sep-09-25 12:00PM	All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy (Zacks) -18.40%
Aug-28-25 09:55AM	Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-27-25 07:00AM	Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-06-25 07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
07:15AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-22-25 07:01AM	Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 (GlobeNewswire) -10.54%
07:00AM	Seres Therapeutics Announces Leadership Transition (GlobeNewswire)
Jun-19-25 10:16AM	Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities (GlobeNewswire)
May-27-25 07:00AM	Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting (GlobeNewswire) -5.74%
May-23-25 12:00PM	Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-16-25 09:55AM	Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade (Zacks)
May-07-25 02:18PM	Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:17AM	Seres Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-29-25 07:00AM	Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases (GlobeNewswire)
Apr-23-25 07:00AM	Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 (GlobeNewswire) +19.24%
Apr-17-25 09:35AM	Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround (Zacks) -7.48%
Mar-14-25 03:04AM	Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... (GuruFocus.com) +8.05%
02:23AM	Q4 2024 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-25 07:00AM	Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) -7.91%
Mar-04-25 07:00AM	Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 (GlobeNewswire) -10.50%
Mar-03-25 07:00AM	Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach (GlobeNewswire)
Jan-16-25 07:00AM	Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale (GlobeNewswire) -5.77%
Jan-10-25 07:15AM	Seres announces new translational biomarker results from SER-155 Phase 1b study (TipRanks)
Jan-09-25 07:00AM	Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates (GlobeNewswire)
Dec-17-24 07:30AM	Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference (TipRanks)
Dec-16-24 07:00AM	Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 05:43AM	Seres SER-155 gains breakthrough status for BSIs reduction (Pharmaceutical Technology) +9.20%
Dec-09-24 07:00AM	FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire)
Nov-22-24 07:00AM	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference (GlobeNewswire) +5.03%
Nov-14-24 02:08AM	Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... (GuruFocus.com)
Nov-13-24 07:23AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -11.10%
07:00AM	Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:00AM	Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 (GlobeNewswire) -6.98%
Sep-30-24 05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Societe des Produits Nestle S.A (GlobeNewswire)
05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Soci t des Produits Nestl S.A (GlobeNewswire)
Sep-27-24 03:26PM	Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestle (Business Wire) +10.44%
Sep-26-24 04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestle Health Science; Sale Expected to Close on September 30 (GlobeNewswire) -9.10%
04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science; Sale Expected to Close on September 30 (GlobeNewswire)
Sep-13-24 07:00AM	Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference (GlobeNewswire)
Sep-12-24 07:00AM	Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire) -8.57%
Sep-04-24 09:35AM	After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) (Zacks)
Aug-15-24 09:55AM	Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now (Zacks)
Aug-14-24 03:09AM	Q2 2024 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.07%
Aug-13-24 07:15AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.97%
07:00AM	Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-24 07:00AM	Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024 (GlobeNewswire) -21.09%
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestle Health Science (GlobeNewswire)
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestl Health Science (GlobeNewswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire) -6.18%
Jun-07-24 04:00PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -28.03% +20.54%
Jun-06-24 07:05AM	Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle (BioPharma Dive) -25.17%
07:00AM	Nestl Health Science agrees to acquire global rights to VOWST, product it launched in June 2023 (PR Newswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestle Health Science (GlobeNewswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestl Health Science (GlobeNewswire)
May-13-24 12:18PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.38%
May-09-24 11:06AM	Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating (MT Newswires) +37.44%
07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
06:30AM	Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating (MT Newswires)
03:11AM	Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
May-08-24 11:54AM	MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -32.49%
08:42AM	Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates (GuruFocus.com)
07:25AM	Seres Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-06-24 04:01PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.72%
09:30AM	Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 (Business Wire)
Apr-09-24 07:00AM	Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT (Business Wire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brady Kelly	See Remarks	Aug 17 '26	Sale	4.55	64	291	8,679	Aug 18 05:33 PM
Shaff Eric D.	Director	Aug 17 '26	Sale	4.55	263	1,197	12,499	Aug 18 05:27 PM
Henn Matthew R	See Remarks	Aug 17 '26	Sale	4.55	81	369	7,995	Aug 18 05:25 PM
DesRosier Thomas	See Remarks	Aug 17 '26	Sale	4.55	82	373	8,117	Aug 18 05:22 PM
TERESA L YOUNG	Officer	May 19 '26	Proposed Sale	7.69	167	1,284		May 19 04:15 PM
Shaff Eric D.	Director	May 18 '26	Sale	7.53	259	1,950	12,040	May 19 04:05 PM
DesRosier Thomas	See Remarks	May 18 '26	Sale	7.53	79	595	7,954	May 19 04:05 PM
Henn Matthew R	See Remarks	May 18 '26	Sale	7.53	77	580	7,838	May 19 04:05 PM
Brady Kelly	See Remarks	May 18 '26	Sale	7.53	59	444	8,562	May 19 04:05 PM
TERESA L YOUNG	Officer	Mar 17 '26	Proposed Sale	9.12	8,553	77,967		Mar 17 04:50 PM
Shaff Eric D.	Director	Feb 15 '26	Sale	8.47	259	2,194	11,577	Feb 18 04:30 PM
Young Teresa L.	See Remarks	Feb 15 '26	Sale	8.47	75	635	8,557	Feb 18 04:30 PM
DesRosier Thomas	See Remarks	Feb 15 '26	Sale	8.47	78	661	7,789	Feb 18 04:30 PM
Henn Matthew R	See Remarks	Feb 15 '26	Sale	8.47	89	754	7,677	Feb 18 04:30 PM
Young Teresa L.	See Remarks	Nov 15 '25	Sale	17.30	1,042	18,027	8,401	Nov 18 04:30 PM
Shaff Eric D.	Director	Nov 15 '25	Sale	17.30	217	3,754	11,113	Nov 18 04:30 PM
DesRosier Thomas	See Remarks	Nov 15 '25	Sale	17.30	76	1,315	7,623	Nov 18 04:30 PM
Henn Matthew R	See Remarks	Nov 15 '25	Sale	17.30	1,257	21,746	7,527	Nov 18 04:30 PM

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

M.B.A.Mr. Richard N. Kender B.S.

President & Chief Scientific OfficerDr. Matthew R. Henn Ph.D.

J.D.Mr. Thomas J. DesRosier Esq.

Executive VP & COOMs. Kelly Brady M.S.

Executive VP & CTOMr. Chris McChalicher

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MCRB

Seres Therapeutics Inc

Upgrade your Finviz experience